Skip to main content
SpringerLink
Log in

Diabetische Nephropathie – Update 2012

Positionspapier der Österreichischen Diabetes Gesellschaft und der Österreichischen Gesellschaft für Nephrologie unter Mitarbeit von

Diabetic nephropathy—update 2012

  • leitlinien für die praxis
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

Summary

Diabetes mellitus is the leading single cause for renal replacement therapy. Its development and progression, however, can be ameliorated by adequate therapy. The present article represents the recommendations of the Austrian Diabetes Association and the Austrian Society for Nephrology for the prevention and treatment of diabetic nephropathy.

Zusammenfassung

Diabetische Nephropathie ist die führende Ursache der Nierenersatztherapie und die häufigste Nierenkrankheit geworden. Die Entwicklung und das Fortschreiten kann durch optimierte Therapie beeinflusst werden. Im vorliegenden Artikel werden die gemeinsamen Empfehlungen der Österreichischen Diabetesgesellschaft und der Österreichischen Gesellschaft für Nephrologie dargestellt.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Similar content being viewed by others

Literatur

  1. KDOQI. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(Suppl 1):1–266.

    Google Scholar 

  2. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.

    Article  PubMed  CAS  Google Scholar 

  3. Levey AS, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461–70.

    PubMed  CAS  Google Scholar 

  4. Levey A, Coresh J, Greene T, Marsh J, Stevens LA, Kusek J, Van Lente F. Expressing the MDRD study equation for estimating GFR with IDMS traceable (gold standard) serum creatinine values. J Am Soc Nephrol. 2005;16(Abstractissue):October 2005: 69A.

    Google Scholar 

  5. Levey AS et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.

    PubMed  Google Scholar 

  6. Kalantar-Zadeh K, Amin AN. Toward more accurate detection and risk stratification of chronic kidney disease. JAMA. 2012;307(18):1976–7.

    Article  PubMed  CAS  Google Scholar 

  7. Kramer HJ, et al. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289(24):3273–7.

    Article  PubMed  Google Scholar 

  8. Retnakaran R, et al. Risk factors for renal dysfunction in type 2 diabetes: u.k. prospective diabetes study 74. Diabetes. 2006;55(6):1832–9.

    CAS  Google Scholar 

  9. Thomas MC, et al. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (National Evaluation of the Frequency of Renal Impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care. 2009;32(8):1497–502.

    Article  PubMed  Google Scholar 

  10. DDG NV, Nierenerkrankungen bei Diabetes im Erwachsenenalter. DDG. 2011. www.deutsche-diabetes-gesellschaft.de.

  11. KDOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney Dis. 2004;43:1–290.

    Google Scholar 

  12. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–85.

    Article  Google Scholar 

  13. Bangalore S, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation. 2011;123(24):2799–810.

    Article  PubMed  CAS  Google Scholar 

  14. Members ATF, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur. Heart J. 2012;33(13):1635–701.

    Article  Google Scholar 

  15. Hochdruckliga EVD, Leitlinien für die Prävention, Erkennung, Diagnostik und Therapie der arteriellen Hypertonie – neue Entwicklungen in der Hochdrucktherapie; update. 2011. www.hochdruckliga.de.

  16. Nilsson PM, What Blood Pressure Goal in Type-2 Diabetes? J Hypertonie. 2011;15(4):9–14.

    Google Scholar 

  17. Ruggenenti P, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941–51.

    Article  PubMed  CAS  Google Scholar 

  18. Haller H, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364(10):907–17.

    Article  PubMed  CAS  Google Scholar 

  19. Lewis JB, et al. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. collaborative study group. Am. J. Kidney Dis. 1999;34(5):809–17.

    Article  PubMed  CAS  Google Scholar 

  20. ADA. Standards of medical care in diabetes – 2012. Diabetes Care. 2012;35(Supplement 1):11–63.

    Google Scholar 

  21. Bakris GL, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375(9721):1173–81.

    Article  PubMed  CAS  Google Scholar 

  22. Mann JFE, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–53.

    Article  PubMed  CAS  Google Scholar 

  23. Redon J, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012;59(1):74–83.

    Article  PubMed  Google Scholar 

  24. Watschinger B. Stellungnahme des Vorstands der ÖGH zur Doppelblockade des RAS. J Hypertonie. 2012;16(1):28.

    Google Scholar 

  25. Joannidis M, Schmid M, Wiedermann CJ. Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis. Wien Klin Wochenschr. 2008;120(23–24):742–8.

    Article  PubMed  CAS  Google Scholar 

  26. Kiski D, et al. Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial. Nephrol Dial Transplant. 2010;25(3):759–64.

    Article  PubMed  CAS  Google Scholar 

  27. KDOQI. Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2):12–154.

    Article  Google Scholar 

  28. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.

    Article  Google Scholar 

  29. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–53.

    Article  Google Scholar 

  30. Lewis EJ, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med. 1993;329(20):1456–62.

    Article  PubMed  CAS  Google Scholar 

  31. Brenner BM, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–9.

    Article  PubMed  CAS  Google Scholar 

  32. Parving HH, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 3. Medizinische Abteilung, Krankenhaus Hietzing der Stadt Wien, und Karl Landsteiner Institut für Stoffwechselerkrankungen und Nephrologie, Wien, Österreich

    Martin Auinger, Roland Edlinger & Rudolf Prager

  2. IV. Interne Abteilung/Bereich Nephrologie, Klinikum Wels-Grieskirchen, Wels, Österreich

    Friedrich Prischl

  3. Klinische Abteilung für Endokrinologie und Stoffwechsel, Universitätsklinik für Innere Medizin III, Medizinische Universität Wien, Wien, Österreich

    Alexandra Kautzky-Willer & Martin Clodi

  4. Klinische Abteilung für Nephrologie, Universitätsklinik für Innere Medizin Graz, Graz, Österreich

    Alexander R. Rosenkranz

  5. Deutsches Diabeteszentrum und Klinik für Stoffwechselerkrankungen, Heinrich Heine Universität, Düsseldorf, Deutschland

    Michael Roden

  6. Klinische Abteilung für Nephrologie, Univ. Klinik für Innere Medizin III, Medizinische Universität Wien, Wien, Österreich

    Marcus Saemann

  7. 1.Medizinische Abteilung, Krankenhaus Rudolfstiftung, Wien, Österreich

    Guntram Schernthaner

Authors
  1. Martin Auinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roland Edlinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Friedrich Prischl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexandra Kautzky-Willer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rudolf Prager
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alexander R. Rosenkranz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Michael Roden
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marcus Saemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Martin Clodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Guntram Schernthaner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Auinger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Auinger, M., Edlinger, R., Prischl, F. et al. Diabetische Nephropathie – Update 2012. Wien Klin Wochenschr 124 (Suppl 2), 42–49 (2012). https://doi.org/10.1007/s00508-012-0262-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-012-0262-6

Search

Navigation